A high ARFIP2 expression correlates with the early recurrence and metastasis in hepatocellular carcinoma (HCC) patients, while a low expression of ARFIP2 inhibits HCC cell invasion and migration. Here, ARFIP2 is linked to hepatocellular carcinoma.